Starpharma Holdings | SPL

Stock Price
0.14
Daily Change
0.01 3.85%
Monthly
22.73%
Yearly
42.11%
Q3 Forecast
0.13
Peers Price Chg Day Year Date
Mesoblast 2.21 0.09 4.25% 138.92% Sep/08
Medical Developments International 0.57 -0.01 -0.87% 35.71% Sep/08
Neuren Pharmaceuticals 20.80 0.32 1.56% 51.27% Sep/08


Starpharma Holdings Ltd traded at 0.14 this Monday September 8th, increasing 0.01 or 3.85 percent since the previous trading session. Looking back, over the last four weeks, Starpharma Holdings gained 22.73 percent. Over the last 12 months, its price rose by 42.11 percent. Looking ahead, we forecast Starpharma Holdings Ltd to be priced at 0.13 by the end of this quarter and at 0.13 in one year, according to Trading Economics global macro models projections and analysts expectations.

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.